Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 May;19(5):597–603. doi: 10.1111/j.1365-2125.1985.tb02686.x

The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition.

N D Bax, G T Tucker, M S Lennard, H F Woods
PMCID: PMC1463847  PMID: 2860914

Abstract

To account for a 40% lowering of the systemic clearance of lignocaine by propranolol treatment it has been proposed that propranolol reduces liver blood flow by 25% and causes a 50% decrease in the intrinsic clearance of lignocaine by enzyme inhibition. In theory, the contribution of direct enzyme inhibition is best evaluated using oral administration of lignocaine when models of hepatic drug clearance predict that propranolol could increase the AUCpo of lignocaine by 100-140%. This hypothesis was tested in six healthy men who received 200 mg lignocaine HCl X H2O orally with and without propranolol pre-treatment (80 mg twice daily for 3 days). Propranolol treatment increased the mean plasma AUCpo of lignocaine by 113 +/- 58 s.d.% (P less than 0.005); it increased the peak plasma lignocaine concentration by 79 +/- 50 s.d.% (P less than 0.025) and it prolonged the elimination half-life of lignocaine by 20 +/- 13 s.d.% (P less than 0.05). Propranolol treatment lowered indocyanine green clearance by 11 +/- 15 s.d.%, but this change was not significant statistically. These experimental results are in accord with the theoretical predictions suggesting that propranolol lowers the systemic clearance of lignocaine mainly by direct inhibition of its metabolism rather than by a lowering of the hepatic blood flow.

Full text

PDF
597

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad A. B., Bennett P. N., Rowland M. Influence of route of hepatic administration on drug availability. J Pharmacol Exp Ther. 1984 Sep;230(3):718–725. [PubMed] [Google Scholar]
  2. Bax N. D., Jones R. W., Lennard M. S., Tucker G. T., Woods H. F. Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in man. Br J Clin Pharmacol. 1985 May;19(5):593–596. doi: 10.1111/j.1365-2125.1985.tb02685.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bax N. D., Lennard M. S., Tucker G. T. Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol. 1981 Dec;12(6):779–784. doi: 10.1111/j.1365-2125.1981.tb01306.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bax N. D., Tucker G. T., Woods H. F. Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol. 1980 Oct;10(4):353–361. doi: 10.1111/j.1365-2125.1980.tb01771.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bennett P. N., Aarons L. J., Bending M. R., Steiner J. A., Rowland M. Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. J Pharmacokinet Biopharm. 1982 Jun;10(3):265–281. doi: 10.1007/BF01059261. [DOI] [PubMed] [Google Scholar]
  6. Browning S., Lawrence D., Livingston A., Morris B. Interactions of drugs active at opiate receptors and drugs active at alpha 2-receptors on various test systems. Br J Pharmacol. 1982 Nov;77(3):487–491. doi: 10.1111/j.1476-5381.1982.tb09322.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. CAESAR J., SHALDON S., CHIANDUSSI L., GUEVARA L., SHERLOCK S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci. 1961 Aug;21:43–57. [PubMed] [Google Scholar]
  8. Conrad K. A., Byers J. M., 3rd, Finley P. R., Burnham L. Lidocaine elimination: effects of metoprolol and of propranolol. Clin Pharmacol Ther. 1983 Feb;33(2):133–138. doi: 10.1038/clpt.1983.20. [DOI] [PubMed] [Google Scholar]
  9. Conrad K. A., Nyman D. W. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther. 1980 Oct;28(4):463–467. doi: 10.1038/clpt.1980.189. [DOI] [PubMed] [Google Scholar]
  10. Deacon C. S., Lennard M. S., Bax N. D., Woods H. F., Tucker G. T. Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility. Br J Clin Pharmacol. 1981 Sep;12(3):429–431. doi: 10.1111/j.1365-2125.1981.tb01240.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Grainger S. L., Keeling P. W., Brown I. M., Marigold J. H., Thompson R. P. Clearance and non-invasive determination of the hepatic extraction of indocyanine green in baboons and man. Clin Sci (Lond) 1983 Feb;64(2):207–212. doi: 10.1042/cs0640207. [DOI] [PubMed] [Google Scholar]
  12. Jordö L., Johnsson G., Lundborg P., Regårdh C. G. Pharmacokinetics of lidocaine in healthy individuals pretreated with multiple doses of metoprolol. Int J Clin Pharmacol Ther Toxicol. 1984 Jun;22(6):312–315. [PubMed] [Google Scholar]
  13. Keenaghan J. B., Boyes R. N. The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther. 1972 Feb;180(2):454–463. [PubMed] [Google Scholar]
  14. LEEVY C. M., MENDENHALL C. L., LESKO W., HOWARD M. M. Estimation of hepatic blood flow with indocyanine green. J Clin Invest. 1962 May;41:1169–1179. doi: 10.1172/JCI104570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McNamara P. J., Slaughter R. L., Pieper J. A., Wyman M. G., Lalka D. Factors influencing serum protein binding of lidocaine in humans. Anesth Analg. 1981 Jun;60(6):395–400. [PubMed] [Google Scholar]
  16. Miners J. O., Wing L. M., Lillywhite K. J., Smith K. J. Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine. Br J Clin Pharmacol. 1984 Dec;18(6):853–860. doi: 10.1111/j.1365-2125.1984.tb02555.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ochs H. R., Carstens G., Greenblatt D. J. Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med. 1980 Aug 14;303(7):373–377. doi: 10.1056/NEJM198008143030705. [DOI] [PubMed] [Google Scholar]
  18. Ochs H. R., Knüchel M., Abernethy D. R., Greenblatt D. J. Dose-independent pharmacokinetics of intravenous lidocaine in humans. J Clin Pharmacol. 1983 Apr;23(4):186–188. doi: 10.1002/j.1552-4604.1983.tb02723.x. [DOI] [PubMed] [Google Scholar]
  19. Ochs H. R., Skanderra D., Abernethy D. R., Greenblatt D. J. Effect of penbutolol on lidocaine kinetics. Arzneimittelforschung. 1983;33(12):1680–1681. [PubMed] [Google Scholar]
  20. Pang K. S., Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977 Dec;5(6):625–653. doi: 10.1007/BF01059688. [DOI] [PubMed] [Google Scholar]
  21. Peet M., Middlemiss D. N., Yates R. A. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients. Lancet. 1980 Nov 1;2(8201):978–978. doi: 10.1016/s0140-6736(80)92135-2. [DOI] [PubMed] [Google Scholar]
  22. Svendsen T. L., Tangø M., Waldorff S., Steiness E., Trap-Jensen J. Effects of propranolol and pindolol on plasma lignocaine clearance in man. Br J Clin Pharmacol. 1982;13(Suppl 2):223S–226S. doi: 10.1111/j.1365-2125.1982.tb01915.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tucker G. T., Bax N. D., Lennard M. S., Al-Asady S., Bharaj H. S., Woods H. F. Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine. Br J Clin Pharmacol. 1984;17 (Suppl 1):21S–28S. doi: 10.1111/j.1365-2125.1984.tb02424.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tucker G. T., Mather L. E. Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet. 1979 Jul-Aug;4(4):241–278. doi: 10.2165/00003088-197904040-00001. [DOI] [PubMed] [Google Scholar]
  25. Tucker G. T., Wiklund L., Berlin-Wahlen A., Mather L. E. Hepatic clearance of local anesthetics in man. J Pharmacokinet Biopharm. 1977 Apr;5(2):111–122. doi: 10.1007/BF01066215. [DOI] [PubMed] [Google Scholar]
  26. Westaby D., Bihari D. J., Gimson A. E., Crossley I. R., Williams R. Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. Gut. 1984 Feb;25(2):121–124. doi: 10.1136/gut.25.2.121. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES